- Home
- PASG vs SCNX Comparison
PASG vs SCNX Comparison
Compare PASG & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PASG | SCNX |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | 27 | 9 |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 15.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PASG | SCNX |
|---|---|---|
| Price | $4.61 | $0.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $14.00 | $1.50 |
| AVG Volume (30 Days) | 36.2K | ★ 884.0K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,097.38 |
| Revenue Next Year | N/A | $239.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.29 | $0.24 |
| 52 Week High | $20.00 | $2.60 |
Technical Indicators
Market Signals| Indicator | PASG | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 53.71 |
| Support Level | $4.25 | $0.37 |
| Resistance Level | $5.04 | $0.43 |
| Average True Range (ATR) | 0.25 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 41.79 | 53.44 |
Price Performance
Historical ComparisonAbout PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
About SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.